Toronto, Ontario--(Newsfile Corp. – April 26, 2022) - Psyched Wellness Ltd. (CSE: PSYC) (the "Company" or "Psyched"), a life sciences company focused on the production and distribution of health and wellness products derived from the Amanita Muscaria mushroom , is pleased to announce the company KGK, a licensed CRO in Canada, has reported recent findings from the analysis of the intestinal epithelial immune receptor expression study performed in conjunction with the 90-day oral toxicity study with Amanita Muscaria Extract (AME-1). The in vivo study via oral supplementation with AME-1 focused on the potential bioactive effects on the immune receptors Toll-like Receptor-2 (TLR-2) and Dectin-1, both of which are found on the surface of gut epithelial cells. The Toll-like receptors are an important family within the innate immune system and play a vital role in host-defense mechanisms against pathogens. The main function of TLRs is the ability to recognize numerous pathogens, thus activating the host-defense mechanism through the induction of antimicrobial activity. Dectin-1 is a cell surface pathogen recognition receptor that recognizes soluble and /or particulate forms of β-1,3 or β-1,6-glucans and, like Toll-like receptors, plays an important role in the host-defense mechanism as well.
The recent results of the in vivo study showed only a modest increase in TLR-2 and Dectin-1 receptors, but this was not a significant finding. It could be interpreted that the challenge of continuous dosing of AME-1 resulted in maximal cell surface expression of TLR-2 and Dectin-1, thus seeing only a modest positive upregulation of cell surface membrane expression. However, the sustained upregulation of both TLR-2 and Dectin-1 receptors indicates innate immune mechanisms that were primed and maintained throughout the course of the 90-day oral study. Furthermore, there was no downregulation of either surface receptor type, nor was there any over priming or stimulating effect which would have negatively impacted the immune system through the production of pro-inflammatory cytokines.
“The importance of these in vivo findings indicates an innate immune priming biological activity, and this is preserved during the 90-day study. The potential priming effect and maintenance result in a more efficient response to an invading pathogen, thus promoting greater gut health and increased health and wellness of the individual. There was no over stimulation or negative effects with long -term use of AME-1 in terms of gut health and wellness. This is another key finding in the further understanding of the effects of AME-1 on health and wellness.” says Brian Tancowny a scientific advisor for Psyched Wellness.
Neither the Canadian Securities Exchange nor its Regulation Services Provider have reviewed or accept responsibility for the adequacy or accuracy of this release.
About Psyched Wellness Ltd.:
Psyched Wellness Ltd. is a Canadian-based health supplements company dedicated to the distribution of mushroom-derived products and associated consumer packaged goods. The Company’s objective is to create premium mushroom-derived products that have the potential to become a leading North American brand in the emerging functional food category. The Company is in the process of developing a line of Amanita muscaria-derived water-based extracts, teas and capsules designed to help with three health objectives: promote stress relief, relaxation and assist with restful sleeping.
Cautionary Statement Regarding Forward Looking Information
This press release contains “forward-looking information” within the meaning of applicable Canadian securities legislation. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company’s current belief or assumptions as to the outcome and timing of such future events. The forward-looking information and forward- looking statements contained herein include, but are not limited to, statements regarding: the ability of the Company to develop Amanita Muscaria-derived products; the safety of Amanita Muscaria consumption and the safety and purity of any extracts thereof; and (ii) the uses and potential benefits of Amanita Muscaria.
Forward-looking information in this news release are based on certain assumptions and expected future events, namely: the Company’s ability to continue as a going concern; the Company’s ability to continue to develop its mushroom-derived products and associated consumer packaged goods; continued approval of the Company’s activities by the relevant governmental and/or regulatory authorities; and the continued growth of the Company.
These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including but not limited to: the potential inability of the Company to continue as a going concern; risks associated with potential governmental and/or regulatory action with respect to the Company’s operations; competition within the psychedelics market; risks with respect to the safety of Amanita Muscaria consumption and the safety and purity of any extracts thereof; and the risk that there is no potential benefit of Amanita Muscaria consumption.
Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.
Forward-looking statements contained in this news release are expressly qualified by this cautionary statement and reflect the Company’s expectations as of the date hereof and are subject to change thereafter. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.
For further information, please contact:
Chief Executive Officer
Psyched Wellness Ltd.
t: (647) 400-8494
Tim Regan/Sophia Bashford
KCSA Strategic Communications
t: (978) 505-2478